NOX4 and Related Biomarkers in ADPKD

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT04630613
Status
Recruiting
Apply to this trial

Conditions

  • Autosomal Dominant Polycystic Kidney Disease

Eligibility Criteria

Sex
ALL
Age
15 Years - 40 Years
Healthy Volunteers
Not accepted

Study Details

To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Key Dates

Start date
Jul 21, 2020
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Patients with a previous diagnosis of ADPKD
    Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.

Primary Outcome Measure

NOX4 levels [ Time Frame: Baseline ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Ahmed Abdelfattah
[email protected]
Maria V Irazabal, M.D., Ph.D.
[email protected]
507-884-5628
Maria V Irazabal, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies